Hepatitis C
The World Health Organization
is working to eliminate Hep C by 2030.*1,2
whilst NHS England aims to eliminate Hep C by 2025,
and the Scottish government is aiming for 2024.2-4
Why choose Maviret for community treatment?
Pangenotypic6,7
- Simplifies the treatment pathway, allowing more patients to be treated
8-week treatment duration for treatment-naïve patients6,2
- Ideal for community-based settings, particularly for patients who may be difficult to engage
Once-daily regimen6
- No minimum calorie requirements or additional ribavirin
- No baseline or viral load testing
- No need to routinely monitor liver function
Maviret is indicated for the treatment of chronic hepatitis C virus (HCV) infection, genotypes 1-6, in adults and in adolescents aged 12 to <18 years with compensated liver disease. Maviret may be used for a minimum of 12 weeks in liver and kidney transplant recipients - see SmPC for specific genotypes.
*Elimination defined by WHO as achieving 90% reduction in new chronic infections and a 65% reduction in mortality due to viral hepatitis.1
AE = adverse event.
References:
- The World Health Organization (WHO). Hepatitis C. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c (accessed December 2020).
- All-Party Parliamentary Group on Liver Health Inquiry Report. Eliminating Hepatitis C in England. March 2018. Available at: www.appghep.org.uk/reports/ (accessed December 2020).
- NHS England NHS England sets out plans to be first in the world to eliminate Hepatitis C. 29 January 2018. Available at: www.england.nhs.uk/2018/01/hepatitis-c-2/ (accessed December 2020).
- Scottish Government. Eliminating hepatitis C. 31 July 2019. Available at: www.gov.scot/news/eliminating-hepatitis-c/ (accessed December 2020).
- Ward JW. The Lancet 2020; DOI: https://doi.org/10.1016/S0140-6736(20)32282-0 (accessed December 2020).
- Maviret Summary of Product Characteristics. AbbVie Ltd. Available at: www.medicines.org.uk
- European Association for the Study of the Liver. J Hepatol. 2018; 69(2): 461−511.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk .
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
UK-MAVI-210016. Date of preparation: March 2021